A mutated version of Myc is found in many cancers, which causes Myc to be constitutively (persistently) expressed. This leads to the unregulated expression of many genes, some of which are involved in cell proliferation, and results in the formation of cancer. A common human translocation involving Myc is is critical to the development of most cases of Burkitt's Lymphoma. Malfunctions in Myc have also been found in carcinoma of the cervix, colon, breast, lung and stomach. Myc is thus viewed as a promising target for anti-cancer drugs.
In the human genome, Myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes through binding on Enhancer Box sequences (E-boxes) and recruiting histone acetyltransferases (HATs). This means that in addition to its role as a classical transcription factor, Myc also functions to regulate global chromatin structure by regulating histone acetylation both in gene-rich regions and at sites far from any known gene.
Myc gene was first discovered in Burkitt's lymphoma patients. In Burkitt's lymphoma, cancer cells show chromosomal translocations, in which Chromosome 8 is frequently involved. Cloning the break-point of the fusion chromosomes revealed a gene that was similar to myelocytomatosis viral oncogene (v-Myc). Thus, the newfound cellular gene was named c-Myc.
Myc protein belongs to Myc family of transcription factors, which also includes N-Myc and L-Myc genes. Myc family of transcription factors contain bHLH/LZ (basic Helix-Loop-Helix Leucine Zipper) domain. Myc protein, through its bHLH domain can bind to DNA, while the leucine zipper domain allows the dimerization with its partner Max, another bHLH transcription factor.
Myc mRNA contains an IRES (internal ribosome entry site) that allows the RNA to be translated into protein when 5' cap-dependent translation is inhibited, such as during viral infection.
Myc protein is a transcription factor that activates expression of many genes through binding on consensus sequences (Enhancer Box sequences (E-boxes)) and recruiting histone acetyltransferases (HATs). It can also act as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication.
Myc is activated upon various mitogenic signals such as Wnt, Shh and EGF (via the MAPK/ERK pathway). By modifying the expression of its target genes, Myc activation results in numerous biological effects. The first to be discovered was its capability to drive cell proliferation (upregulates cyclins, downregulates p21), but it also plays a very important role in regulating cell growth (upregulates ribosomal RNA and proteins), apoptosis (downregulates Bcl-2), differentiation, and stem cell self-renewal. Myc is a very strong proto-oncogene and it is very often found to be upregulated in many types of cancers. Myc overexpression stimulates gene amplification, presumably through DNA over-replication.
There have been several studies that have clearly indicated Myc's role in cell competition.
c-Myc induces AEG-1 or MTDH gene expression and in turn itself requires AEG-1 oncogene for its expression.
Myc-nick is a cytoplasmic form of Myc produced by a partial proteolytic cleavage of full-length c-Myc and N-Myc. Myc cleavage is mediated by the calpain family of calcium-dependent cytosolic proteases.
The functions of Myc-nick are currently under investigation, but this new Myc family member was found to regulate cell morphology, at least in part, by interacting with acetyl transferases to promote the acetylation of α-tubulin. Ectopic expression of Myc-nick accelerates the differentiation of committed myoblasts into muscle cells.
Except for early response genes, Myc universally upregulates gene expression. Furthermore the upregulation is nonlinear. Genes whose expression is already significantly upregulated in the absence of Myc are strongly boosted in the presence of Myc, whereas genes whose expression is low in the absence Myc get only a small boost when Myc is present.
Inactivation of SUMO-activating enzyme (SAE1 / SAE2) in the presence of Myc hyperactivation results in mitotic catastrophe and cell death in cancer cells. Hence inhibitors of SUMOylation may be a possible treatment for cancer.
Amplification of the MYC gene was found in a significant number of epithelial ovarian cancer cases. In TCGA datasets, the amplification of Myc occurs in several cancer types, including breast, colorectal, pancreatic, gastric, and uterine cancers.
In the experimental transformation process of normal cells into cancer cells, the MYC gene can cooperate with the RAS gene.
During the discovery of Myc gene, it was realized that chromosomes that translocate to Chromosome 8 contained immunoglobulin genes at the break-point. Enhancers that normally drive expression of immunoglobin genes now lead to overexpression of Myc proto-oncogene in lymphoma cells. To study the mechanism of tumorigenesis in Burkitt's lymphoma by mimicking expression pattern of Myc in these cancer cells, transgenic mouse models were developed. Myc gene placed under the control of IgM heavy chain enhancer in transgenic mice gives rise to mainly lymphomas. Later on, in order to study effects of Myc in other types of cancer, transgenic mice that overexpress Myc in different tissues (liver, breast) were also made. In all these mouse models overexpression of Myc causes tumorigenesis, illustrating the potency of Myc oncogene.
^Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R (July 2007). "Non-transcriptional control of DNA replication by c-Myc". Nature448 (7152): 445–51. doi:10.1038/nature05953. PMID17597761.
^Denis N, Kitzis A, Kruh J, Dautry F, Corcos D (August 1991). "Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc". Oncogene6 (8): 1453–7. PMID1886715.
^Clavería C, Giovinazzo G, Sierra R, Torres M (August 2013). "Myc-driven endogenous cell competition in the early mammalian embryo". Nature500 (7460): 39–44. doi:10.1038/nature12389. PMID23842495.
^de Alboran IM, O'Hagan RC, Gärtner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW (January 2001). "Analysis of C-MYC function in normal cells via conditional gene-targeted mutation". Immunity14 (1): 45–55. doi:10.1016/S1074-7613(01)00088-7. PMID11163229.
^Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D (September 2012). "c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells". Cell151 (1): 68–79. doi:10.1016/j.cell.2012.08.033. PMID23021216.
^Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF (January 2012). "A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis". Science335 (6066): 348–53. doi:10.1126/science.1212728. PMID22157079.
^Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ (September 2013). "Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies". Gynecol. Oncol.130 (3): 554–9. doi:10.1016/j.ygyno.2013.06.019. PMID23791828.
^Land H, Parada LF, Weinberg RA (1983). "Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.". Nature.304 (5927): 596–602. PMID6308472.
^Radner H, el-Shabrawi Y, Eibl RH, Brüstle O, Kenner L, Kleihues P, Wiestler OD (1993). "Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose". Acta neuropathologica86 (5): 456–465. PMID8310796.
^ abLi H, Lee TH, Avraham H (2002). "A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer". J. Biol. Chem.277 (23): 20965–73. doi:10.1074/jbc.M112231200. PMID11916966.
^Zhou C, Liu J (2003). "Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells". Biochem. Biophys. Res. Commun.303 (1): 130–6. doi:10.1016/s0006-291x(03)00318-8. PMID12646176.
^Wang Q, Zhang H, Kajino K, Greene MI (1998). "BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells". Oncogene17 (15): 1939–48. doi:10.1038/sj.onc.1202403. PMID9788437.
^ abJin Z, Gao F, Flagg T, Deng X (2004). "Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation". J. Biol. Chem.279 (38): 40209–19. doi:10.1074/jbc.M404056200. PMID15210690.
^Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y (1999). "Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase". J. Biol. Chem.274 (46): 32580–7. doi:10.1074/jbc.274.46.32580. PMID10551811.
^ abMcMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD (1998). "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins". Cell94 (3): 363–74. doi:10.1016/s0092-8674(00)81479-8. PMID9708738.
^ abCheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV (1999). "c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function". Nat. Genet.22 (1): 102–5. doi:10.1038/8811. PMID10319872.
^ abMac Partlin M, Homer E, Robinson H, McCormick CJ, Crouch DH, Durant ST, Matheson EC, Hall AG, Gillespie DA, Brown R (2003). "Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX". Oncogene22 (6): 819–25. doi:10.1038/sj.onc.1206252. PMID12584560.
^Blackwood EM, Eisenman RN (1991). "Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc". Science251 (4998): 1211–7. doi:10.1126/science.2006410. PMID2006410.
^Billin AN, Eilers AL, Queva C, Ayer DE (1999). "Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors". J. Biol. Chem.274 (51): 36344–50. doi:10.1074/jbc.274.51.36344. PMID10593926.
^Gupta K, Anand G, Yin X, Grove L, Prochownik EV (1998). "Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc". Oncogene16 (9): 1149–59. doi:10.1038/sj.onc.1201634. PMID9528857.
^Nair SK, Burley SK (2003). "X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors". Cell112 (2): 193–205. doi:10.1016/s0092-8674(02)01284-9. PMID12553908.
^FitzGerald MJ, Arsura M, Bellas RE, Yang W, Wu M, Chin L, Mann KK, DePinho RA, Sonenshein GE (1999). "Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc". Oncogene18 (15): 2489–98. doi:10.1038/sj.onc.1202611. PMID10229200.
^Meroni G, Cairo S, Merla G, Messali S, Brent R, Ballabio A, Reymond A (2000). "Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?". Oncogene19 (29): 3266–77. doi:10.1038/sj.onc.1203634. PMID10918583.
^Taira T, Maëda J, Onishi T, Kitaura H, Yoshida S, Kato H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H (1998). "AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC". Genes Cells3 (8): 549–65. doi:10.1046/j.1365-2443.1998.00206.x. PMID9797456.
^Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K, Funa K (2001). "Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor". J. Cell. Sci.114 (Pt 8): 1533–44. PMID11282029.
^Taira T, Sawai M, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H (1999). "Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y". J. Biol. Chem.274 (34): 24270–9. doi:10.1074/jbc.274.34.24270. PMID10446203.
^Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K, Kohno K (2002). "p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression". J. Biol. Chem.277 (35): 31694–702. doi:10.1074/jbc.M200266200. PMID12080043.
^ abcdefLiu X, Tesfai J, Evrard YA, Dent SY, Martinez E (2003). "c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation". J. Biol. Chem.278 (22): 20405–12. doi:10.1074/jbc.M211795200. PMID12660246.
^Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H (1998). "MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc". J. Biol. Chem.273 (45): 29794–800. doi:10.1074/jbc.273.45.29794. PMID9792694.
^Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM, Nagashima K, Ariga H (2001). "MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer". J. Biol. Chem.276 (48): 45137–44. doi:10.1074/jbc.M106127200. PMID11567024.
^ abFeng XH, Liang YY, Liang M, Zhai W, Lin X (2002). "Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B)". Mol. Cell9 (1): 133–43. doi:10.1016/s1097-2765(01)00430-0. PMID11804592.
^Otsuki Y, Tanaka M, Kamo T, Kitanaka C, Kuchino Y, Sugimura H (2003). "Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts". J. Biol. Chem.278 (7): 5132–40. doi:10.1074/jbc.M206733200. PMID12446731.
^Shrivastava A, Saleque S, Kalpana GV, Artandi S, Goff SP, Calame K (1993). "Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc". Science262 (5141): 1889–92. doi:10.1126/science.8266081. PMID8266081.
^Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Möröy T, Bartek J, Massagué J, Hänel F, Eilers M (2001). "Repression of p15INK4b expression by Myc through association with Miz-1". Nat. Cell Biol.3 (4): 392–9. doi:10.1038/35070076. PMID11283613.
Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002). "The proto-oncogene c-myc in hematopoietic development and leukemogenesis". Oncogene21 (21): 3414–21. doi:10.1038/sj.onc.1205400. PMID12032779.
Pelengaris S, Khan M, Evan G (2002). "c-MYC: more than just a matter of life and death". Nat. Rev. Cancer2 (10): 764–76. doi:10.1038/nrc904. PMID12360279.
Bernstein PL, Herrick DJ, Prokipcak RD, Ross J (1992). "Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant". Genes Dev.6 (4): 642–54. doi:10.1101/gad.6.4.642. PMID1559612.
Seth A, Alvarez E, Gupta S, Davis RJ (1992). "A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression". J. Biol. Chem.266 (35): 23521–4. PMID1748630.
Takahashi E, Hori T, O'Connell P, Leppert M, White R (1991). "Mapping of the MYC gene to band 8q24.12----q24.13 by R-banding and distal to fra(8)(q24.11), FRA8E, by fluorescence in situ hybridization". Cytogenet. Cell Genet.57 (2–3): 109–11. doi:10.1159/000133124. PMID1914517.
Blackwood EM, Eisenman RN (1991). "Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc". Science251 (4998): 1211–7. doi:10.1126/science.2006410. PMID2006410.
Guilhot S, Petridou B, Syed-Hussain S, Galibert F (1989). "Nucleotide sequence 3' to the human c-myc oncogene; presence of a long inverted repeat". Gene72 (1–2): 105–8. doi:10.1016/0378-1119(88)90131-X. PMID3243428.
Hann SR, King MW, Bentley DL, Anderson CW, Eisenman RN (1988). "A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas". Cell52 (2): 185–95. doi:10.1016/0092-8674(88)90507-7. PMID3277717.